Serum progastrin-releasing peptide in pneumonia, COPD, and early-stage lung cancers
Author Information
Author(s): Begolli Gramos, Lukić Maja, Rumora Lada, Čorak Lorna, Vukić Dugac Andrea, Jakopović Marko, Samaržija Miroslav, Tomaš Ilijan, Knežević Jelena, Debeljak Željko
Primary Institution: University Hospital Centre Zagreb
Hypothesis
The study aims to compare serum proGRP concentration in pneumonia, chronic obstructive pulmonary disease (COPD), and early-stage primary lung cancers.
Conclusion
ProGRP concentrations in pneumonia and COPD patients were found to be higher than in early-stage lung cancer patients.
Supporting Evidence
- In pneumonia and COPD, median proGRP levels were > 50 ng/L.
- Median proGRP levels were < 40 ng/L in early-stage lung adenocarcinoma and squamous cell carcinoma.
- ProGRP levels in pneumonia and COPD may exceed the SCLC cut-off of 100 ng/L.
- Statistical analysis showed significant differences in proGRP levels between pneumonia/COPD and early-stage lung cancers.
Takeaway
This study found that patients with pneumonia and COPD have higher levels of a specific protein in their blood compared to those with early-stage lung cancer.
Methodology
An observational study was conducted to assess serum proGRP against other lung cancer markers in pneumonia, COPD, and early-stage lung cancers.
Potential Biases
The study design limits the significance of the findings due to the small sample size.
Limitations
The sample size is relatively low, and other causes of elevated serum proGRP were not analyzed.
Participant Demographics
The study included 198 patients, with a median age of 70 years for pneumonia/COPD and 63 years for early-stage lung cancer; predominantly male and smokers.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website